Peramivir: A Review in Uncomplicated Influenza
- 90 Downloads
Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of peramivir in this indication and summarizes its pharmacological properties. In large, randomized, double-blind, multicentre trials in previously healthy adults with uncomplicated influenza, a single infusion of peramivir 600 mg significantly shortened the median time to resolution of influenza symptoms compared with placebo and was noninferior to the recommended oseltamivir regimen in terms of this primary outcome. Albeit data are limited, results from a noncomparative phase 3 trial in paediatric patients (≈ 95% of whom were aged ≥ 2 years) with acute uncomplicated influenza receiving the recommended dose of peramivir were generally consistent with those in adults. Peramivir was generally well tolerated in children and adults participating in these clinical trials, with most adverse events of mild to moderate intensity. Given its simple single-dose regimen and with intravenous administration offering a potential advantage over oral administration in individuals with nausea, vomiting or having difficulty in swallowing, peramivir provides an additional option for treating uncomplicated influenza infection in adults and children from the age of 2 years.
During the peer review process, the manufacturer of peramivir was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 2.European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza. 2017. http://www.ecdc.europa.eu. Accessed 2 Aug 2018.
- 12.BioCryst. RAPIVAB® (peramivir injection): US prescribing information. 2018. https://www.fda.gov/. Accessed 2 Aug 2018.
- 17.Pascua PNQ, Mostafa HH, Marathe BM, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep. 2017;7(7345):1–15.Google Scholar
- 24.World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility: Geneva, November 2011 and June 2012. Wkly Epidmiol Rec. 2012;87:369–74.Google Scholar
- 29.BioCryst. Alpivab (peramivir): summary of product characteristics. 2018. http://www.ema.europa.eu/. Accessed 2 Aug 2018.
- 36.Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study. Open Forum Infect Dis. 2017;4(3 ofx129):1–8.Google Scholar
- 38.Public Health England. PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza. 2017. http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/648758/PHE_guidance_antivirals_influenza_201718_FINAL.pdf. Accessed 2 Aug 2018.
- 39.European Medicines Agency. Oseltamavir: summary of product characteristics. 2012. http://www.ema.europa.eu. Accessed 2 Aug 2018.
- 40.GlaxoSmithKline UK. Relenza 5 mg/dose inhalation powder: summary of product characteristics. 2015. http://www.medicines.org.uk/. Accessed 2 Aug 2018.